ResMed Inc. (RMD): Price and Financial Metrics

ResMed Inc. (RMD): $219.30

-13.60 (-5.84%)

POWR Rating

Component Grades














  • Stability is the dimension where RMD ranks best; there it ranks ahead of 86.98% of US stocks.
  • The strongest trend for RMD is in Quality, which has been heading down over the past 178 days.
  • RMD ranks lowest in Momentum; there it ranks in the 10th percentile.

RMD Stock Summary

  • RESMED INC's market capitalization of $33,594,560,291 is ahead of 93% of US-listed equities.
  • With a one year PEG ratio of 1,054.07, RESMED INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.38% of US stocks.
  • The price/operating cash flow metric for RESMED INC is higher than 94.47% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RESMED INC are A, HZNP, TEL, ABMD, and ITT.
  • RMD's SEC filings can be seen here. And to visit RESMED INC's official web site, go to

RMD Valuation Summary

  • RMD's EV/EBIT ratio is 35.3; this is 305.75% higher than that of the median Healthcare stock.
  • Over the past 243 months, RMD's price/sales ratio has gone up 4.8.

Below are key valuation metrics over time for RMD.

Stock Date P/S P/B P/E EV/EBIT
RMD 2022-12-02 9.4 9.9 43.4 35.3
RMD 2022-12-01 9.3 9.8 42.7 34.7
RMD 2022-11-30 9.3 9.8 42.9 34.9
RMD 2022-11-29 9.0 9.5 41.6 33.8
RMD 2022-11-28 9.1 9.6 42.0 34.2
RMD 2022-11-25 9.3 9.8 42.8 34.8

RMD Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 70.47%.
  • The 2 year cash and equivalents growth rate now stands at -42.82%.
  • The year over year revenue growth rate now stands at 14.51%.
RMD's revenue has moved up $1,284,209,000 over the prior 52 months.

The table below shows RMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3,624.405 461.466 786.302
2022-06-30 3,578.127 351.147 779.437
2022-03-31 3,539.492 498.186 779.476
2021-12-31 3,443.759 577.025 521.983
2021-09-30 3,348.896 527.062 499.746
2021-06-30 3,196.825 736.718 474.505

RMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RMD has a Quality Grade of C, ranking ahead of 68.39% of graded US stocks.
  • RMD's asset turnover comes in at 0.72 -- ranking 50th of 186 Medical Equipment stocks.
  • PEYE, MMSI, and SIEN are the stocks whose asset turnover ratios are most correlated with RMD.

The table below shows RMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.720 0.569 0.426
2021-06-30 0.691 0.575 0.410
2021-03-31 0.673 0.582 0.379
2020-12-31 0.676 0.582 0.342
2020-09-30 0.670 0.583 0.321
2020-06-30 0.672 0.581 0.300

RMD Price Target

For more insight on analysts targets of RMD, see our RMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $261.67 Average Broker Recommendation 1.91 (Hold)

RMD Stock Price Chart Interactive Chart >

Price chart for RMD

RMD Price/Volume Stats

Current price $219.30 52-week high $268.77
Prev. close $232.90 52-week low $189.40
Day low $219.19 Volume 333,585
Day high $229.81 Avg. volume 552,149
50-day MA $221.52 Dividend yield 0.76%
200-day MA $224.35 Market Cap 32.12B

ResMed Inc. (RMD) Company Bio

ResMed is a San DiegoCalifornia-based medical device company. It primarily provides cloud-connectable CPAP devices and masks for the treatment of sleep apnea, as well as devices and masks for treating chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other respiratory-related conditions. It also provides a self-monitoring digital sensor and app for people who use inhalers to treat COPD or asthma via Propeller Health, which ResMed acquired in 2019. (Source:Wikipedia)  

RMD Latest News Stream

Event/Time News Detail
Loading, please wait...

RMD Latest Social Stream

Loading social stream, please wait...

View Full RMD Social Stream

Latest RMD News From Around the Web

Below are the latest news stories about RESMED INC that investors may wish to consider to help them evaluate RMD as an investment opportunity.

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Yahoo | November 24, 2022

ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions

- Acquisition expands ResMed’s SaaS business to Germany, first non-U.S. market - Outpatient therapy services added to ResMed’s growing SaaS offering portfolio - Purchase price of €958.6 million (US$997.5 million); deal will be accretive to non-GAAP diluted earnings per share SAN DIEGO and HILDESHEIM, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wi

Yahoo | November 22, 2022

ResMed Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Support Growth, Development, and Production of Digital Health Solutions

ResMed Tuas Facility Ribbon Cutting From to left to right: Brendan Mullins, Vice President of Manufacturing, ResMed; William Hodgman, Australian High Commissioner to Singapore; Jonathan Kaplan, United States Ambassador to Singapore; Peter Farrell, Chairman, ResMed; Mick Farrell, Chief Executive Officer, ResMed; Mr Tharman Shanmugaratnam, Senior Minister, Singapore; Tan Kong Hwee, Executive Vice President, Economic Development Board; Rob Douglas, President and Chief Operating Officer, ResMed; And

Yahoo | November 16, 2022

Here's Why Shareholders Will Not Be Complaining About ResMed Inc.'s (NYSE:RMD) CEO Pay Packet

It would be hard to discount the role that CEO Mick Farrell has played in delivering the impressive results at ResMed...

Yahoo | November 10, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Resmed (RMD) and Merck & Company (MRK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Resmed (RMD – Research Report) and Merck & Company (MRK – Research Report). Insulet (PODD) J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Insulet yesterday and set a price target of $300.00. The company's shares closed last Friday at $255.55. According to TipRanks.

Brian Anderson on TipRanks | October 31, 2022

Read More 'RMD' Stories Here

RMD Price Returns

1-mo 4.20%
3-mo -0.41%
6-mo 3.72%
1-year -13.25%
3-year 49.07%
5-year 170.76%
YTD -15.15%
2021 23.41%
2020 38.33%
2019 37.85%
2018 36.38%
2017 39.06%

RMD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7988 seconds.